Search

Positivity... just a paw away

Data released by Boehringer Ingelheim shows the 96% of dog owners and 91% of cat owners claim their pet has a positive impact on their daily lives.

Boehringer Ingelheim acquires a stake in SoundTalks

Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme

View from Both Sides of the Table

Scott DeWire, US Head of BD&L shares experiences that have taught him first-hand the foundations of successful partnerships

FreVAX smartphone application piglet vaccination

New FreVAX™ smartphone application brings piglet vaccination to another level

First Translational Medicine Award awarded

The Award recognizes the research that has the highest translational potential

Blue internal teat sealant now in dairy mastitis portfolio

Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolio

Duluth

FRONTLINE becomes Brand of the Year 2019-2020

FRONTLINE becomes ‘Brand of the Year’ 2019-2020 in World Branding Awards

Hypertension

Click here for more information on Hypertension

FRONTLINE® becomes Brand of the Year 2021-22

FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards

Boehringer Ingelheim partners with GNA Biosolutions

Boehringer Ingelheim partners with GNA Biosolutions to develop African swine fever diagnostic test.

clinical_collaboration_with_Mirati

Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.

Winners of 2020 BVDzero Case Awards

Winners of 2020 BVDzero Case Awards announced. 10 top clinical cases will receive a total prize of 15,000 euros.

Vaccine prevent calf diarrhea

Fencovis® is the first vaccine to prevent calf diarrhea caused by E. coli F5 and bovine rotavirus and reduce severity of calf diarrhea caused by bovine coronavirus

Boehringer Ingelheim collaborates with Circle Pharma

Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells

Ingelheim

The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.

Vaccine bluetongue virus serotype 3 sheep cattle

BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.

2021 PRRS Research Award winners announced

The 2021 European PRRS Research Award winners announced

Clinical trials deliver medical breakthroughs – but how do they happen?

Clinical trials deliver medical breakthroughs – but how do they happen? Prof. Dr Martina Brueckmann talks about her role getting new drugs to trial.

PREVEXXION® RN: Marek’s disease vaccine available in EU UK

Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.

Advance study vaccinating increased milk production

[New ADVANCE study shows vaccinating with Bovela® results in increased milk production

Winners of the 2019 European PRRS Research Award

Winners of the 2019 European PRRS Research Award announced.

Over 100 billion birds vaccinated with VAXXITEK

Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.